RecruitingNCT05744466

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region

Sponsor

Bristol-Myers Squibb

Enrollment

1,500 participants

Start Date

Sep 30, 2022

Study Type

OBSERVATIONAL

Conditions

Psoriasis

Summary

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Have been diagnosed with plaque psoriasis by a dermatologist
Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

Exclusion Criteria2

Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

Interested in this trial?

Get notified about updates and connect with the research team.